-
CHS replies to Quebec’s INESSS following its shocking report on the funding of Hemlibra
The Institut national d’excellence en santé et en services sociaux (INESSS) released its recommendation on funding Hemlibra (emicizumab) for the treatment of severe hemophilia A...
-
Results from a CHS/Novo Nordisk Psychosocial Research Program project now published
In 2018, Jennifer King, social worker at the Saskatchewan Health Authority in Saskatoon, was awarded a grant through the CHS/Novo Nordisk Psychosocial Research Program for...
-
FAQs – COVID-19 vaccine and bleeding disorders
The Association of Hemophilia Clinic Directors of Canada (AHCDC) has issued a message to address the most frequent questions asked with regards to the COVID-19...
-
COVID-19 vaccination guidance for people with bleeding disorders
CLICK HERE to read the joint guidance notice from the World Federation of Hemophilia (WFH), European Association for Haemophilia and Allied Disorders (EAHAD), European Haemophilia Consortium...
-
FDA puts uniQure’s gene therapy clinical programme, HOPE-B, on hold following submission of a safety report
December 21, 2020 – The European Haemophilia Consortium (EHC) has learned that uniQure announced that its haemophilia B gene therapy programme, including the pivotal, phase...